Observational studyCancer science2020

No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.

Eo Toriyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.